The stock of Eli Lilly and Company (NYSE:LLY) decreased by -$0.02 on Tuesday to finish at $553.90, down -0.00 percent. The last five days have seen an average of 1,764,060 shares of common stock traded. 33 times new highs were reached in the current year, with a gain of $188.06. The average number of shares traded over the last 20 days was 3,208,880, while the average volume over the last 50 days totaled 2,816,930.
LLY stock appreciated 21.86% since last month. On 08/04/23, the company’s shares reached a one-month low of $446.89. The stock touched a high of $557.40 on 08/23/23, after rallying from a low of $296.32 in 52 weeks. The price of LLY stock has risen by 51.40% or $188.06 this year, reaching a new high 33 times. Still, the stock price is down -0.63% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
LLY stock investors should be aware that Eli Lilly and Company (LLY) stock had its last reported insider trading activity 2 days ago on Aug 28. On Aug 28, 10% Owner LILLY ENDOWMENT INC sold 37,660 shares at $554.12 each. This transaction resulted in the insider making $20,868,163. On Aug 25, LILLY ENDOWMENT INC sold 63,572 shares at a price of US$554.38. After the transaction, the insider now owns 100,312,939 shares. 10% Owner LILLY ENDOWMENT INC had earlier sold 20,992 shares on Aug 24 for $554.74 a share. The transaction was completed for $11,645,029.
Valuation Metrics
Eli Lilly and Company (LLY) has a trailing price-to-earnings (P/E) ratio of 76.95. Beta for the stock is 0.30. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 17.63, the price-to-book (PB) ratio of 45.03, and the price-to-cash flow ratio of 162.06.
Company paid $1.13 per share in dividends, remained unchanged from $1.13 last year. A $0.15 dividend increase was reported on Monday December 12 2022.
Financial Health
For the three months ended June 29, Eli Lilly and Company’s quick ratio was 0.90, while its current ratio was 1.10, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.64, and the total debt to equity ratio is 1.70. As far as profitability goes, gross margin for the trailing twelve months is 77.80% percent. Eli Lilly and Company’s EBITDA margin for the year ended June 29 was 34.35%, whereas its operating margin stood at 24.20% for the same period. Based on annual data, it had gross profit of $21.91 billion and revenue of $28.54 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. LLY’s return on assets (ROA) during the last 12 months has been 12.70%. There was a 24.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 60.50%.
Earnings Surprise
According to Eli Lilly and Company’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $8.31 billion, while revenues rose by 21.95% to $6.96 billion. It was predicted that Eli Lilly and Company’s quarterly earnings would be $2.11, but it ended up being $1.98, beating the consensus by 6.60%. EBITDA was $2.49 billion for the quarter. At the end of Eli Lilly and Company’s most recent quarter ended June 29, its liabilities totaled 43.66 billion, while its total debt was $18.95 billion. Equity owned by shareholders amounts to $949.29 million.
Technical Picture
Here’s a quick look at Eli Lilly and Company’s (LLY) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 75.88%, suggesting the stock is Overbought, with a 14.70% historical volatility rate.
The stochastic %K and %D were 91.73% and 92.40% respectively, while the average true range (ATR) was 10.54. Based on the 14-day stochastic reading of 90.64%, the RSI (14) reading is 75.18%. On the 9-day MACD Oscillator, the stock is at 3.75, and the 14-day reading is at 8.74.
Analyst Ratings
In its most recent analyst report, Jefferies raised its rating on Eli Lilly and Company (NYSE: LLY) to a Buy. Prior to this, analysts firm rated the stock as a Hold. Analysts have assigned Eli Lilly and Company (LLY) an Overweight rating. LLY is a stock that is recommended for selling by 1 brokerage firm, while 6 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 1 rate it overweight and 21 others recommend it as a buy.
What is LLY’s price target for the next 12 months?
The current consensus forecast for the stock is between $300.00 and $633.00, with a median target price of $590.00. In analyzing these forecasts, the average price target given by analysts for Eli Lilly and Company (LLY) is $545.75.
